
    
      Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine
      in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by
      6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints:
      virological and immunological
    
  